{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:42:00Z","timestamp":1791225720775,"version":"4.1.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Postoperative nausea and vomiting (PONV) continue to be some of the most common and troublesome complications following anesthesia. Oliceridine, a G protein-biased \u00b5-opioid receptor agonist, has the potential to provide effective pain relief while reducing the incidence of opioid-associated side effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The aim of this study is to evaluate the effectiveness and safety of oliceridine for preventing PONV compared with morphine and a placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive search was performed across PubMed\/MEDLINE, Embase (Ovid), and the Cochrane Central Register of Controlled Trials (CENTRAL) from their inception up to 30 September 2025, without any language limitations. Randomized controlled trials (RCTs) comparing oliceridine with morphine or placebo were included. Outcomes included incidence of nausea, vomiting, and other opioid-related adverse events (ORAEs). Pooled risk ratios (RRs) and their corresponding 95% confidence intervals (CIs) were estimated using random-effects models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This meta-analysis included five studies, with a total of 1,767 patients. The pooled analysis showed that oliceridine significantly reduced the incidence of postoperative nausea compared with morphine (risk ratio [RR] = 0.80; 95% confidence interval [CI] = 0.70\u20130.90). In dose-specific analyses, the RRs were 0.58 (95% CI = 0.50\u20130.67) for the 0.1\u00a0mg group, 0.82 (95% CI = 0.74\u20130.92) for the 0.35\u00a0mg group, and 1.00 (95% CI = 0.91\u20131.11) for the 0.5\u00a0mg group. Oliceridine also decreased the risk of postoperative vomiting (RR = 0.55; 95% CI = 0.45\u20130.67) relative to morphine. Subgroup analyses yielded RRs of 0.39 (95% CI = 0.31\u20130.50), 0.54 (95% CI = 0.38\u20130.78), and 0.80 (95% CI = 0.68\u20130.95) for the 0.1\u00a0mg, 0.35\u00a0mg, and 0.5\u00a0mg groups, respectively. Moreover, oliceridine appeared to lower the incidence of opioid-related adverse events, including dizziness (RR = 0.89; 95% CI = 0.76\u20131.04), dry mouth (RR = 0.50; 95% CI = 0.37\u20130.69), pruritus (RR = 0.50; 95% CI = 0.35\u20130.70), and somnolence (RR = 0.61; 95% CI = 0.45\u20130.82). Based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system, the certainty of evidence ranged from moderate to low.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Oliceridine, particularly at 0.1\u20130.35\u00a0mg demand doses, reduces PONV and several opioid-related adverse events compared with morphine while maintaining effective analgesia. However, compared with placebo, typical opioid adverse effects remain. Further large-scale RCTs are warranted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42024604703<\/jats:ext-link>\n                      , identifier PROSPERO (CRD42024604703).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1779641","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:53:14Z","timestamp":1776837194000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Nausea and vomiting as adverse events of oliceridine: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"17","author":[{"given":"Jinfang","family":"Zeng","sequence":"first","affiliation":[{"name":"Department of Anesthesiology and Pain Medicine, Wuxi No.2 People\u2019s Hospital (Jiangnan University Medical Center)","place":["Wuxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Pain Medicine, Wuxi No.2 People\u2019s Hospital (Jiangnan University Medical Center)","place":["Wuxi, China"]},{"name":"Wuxi School of Medicine, Jiangnan University","place":["Wuxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjin","family":"Jian","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Affiliated Hospital of Jiangnan University","place":["Wuxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minmin","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Pain Medicine, Wuxi No.2 People\u2019s Hospital (Jiangnan University Medical Center)","place":["Wuxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1097\/ALN.0b013e318238bba6","article-title":"Molecular mechanisms of opioid receptor-dependent signaling and behavior","volume":"115","author":"Al-Hasani","year":"2011","journal-title":"Anesthesiology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1016\/j.bja.2019.03.006","article-title":"Hot topics in opioid pharmacology: mixed and biased opioids","volume":"122","author":"Azzam","year":"2019","journal-title":"Br. J. Anaesth."},{"key":"B3","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s40122-020-00216-x","article-title":"Oliceridine is associated with reduced risk of vomiting and need for rescue antiemetics compared to morphine: exploratory analysis from two phase 3 randomized placebo and active controlled trials","volume":"10","author":"Beard","year":"2021","journal-title":"Pain Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"8019","DOI":"10.1021\/jm4010829","article-title":"Structure-activity relationships and discovery of a G protein biased \u03bc opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain","volume":"56","author":"Chen","year":"2013","journal-title":"J. Med. Chem."},{"key":"B5","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/ALN.0000000000003441","article-title":"Benefit and risk evaluation of biased \u03bc-receptor agonist oliceridine versus morphine","volume":"133","author":"Dahan","year":"2020","journal-title":"Anesthesiology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"875","DOI":"10.2147\/DDDT.S372612","article-title":"Oliceridine for the management of moderate to severe acute postoperative pain: a narrative review","volume":"17","author":"Daksla","year":"2023","journal-title":"Drug Des. Devel. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12871-023-02078-0","article-title":"Penehyclidine hydrochloride for treating postoperative nausea and vomiting after laparoscopic bariatric surgery: a double-blinded randomized controlled trial","volume":"23","author":"Ding","year":"2023","journal-title":"BMC Anesthesiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.bja.2023.11.008","article-title":"Opioid-free anaesthesia reduces postoperative nausea and vomiting after thoracoscopic lung resection: a randomised controlled trial","volume":"132","author":"Feng","year":"2024","journal-title":"Br. J. Anaesth."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1007\/s40122-021-00299-0","article-title":"Oliceridine exhibits improved tolerability compared to morphine at equianalgesic conditions: exploratory analysis from two phase 3 randomized placebo and active controlled trials","volume":"10","author":"Hammer","year":"2021","journal-title":"Pain Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ejphar.2013.10.037","article-title":"Pathophysiological and neurochemical mechanisms of postoperative nausea and vomiting","volume":"722","author":"Horn","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.bja.2023.06.029","article-title":"Fosaprepitant for postoperative nausea and vomiting in patients undergoing laparoscopic gastrointestinal surgery: a randomised trial","volume":"131","author":"Huang","year":"2023","journal-title":"Br. J. Anaesth."},{"key":"B12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.2344\/anpr-68-03-12","article-title":"Cross-sectional study of PONV risk factors for oral surgery after intubated general anesthesia with total intravenous anesthesia","volume":"69","author":"Ishikawa","year":"2022","journal-title":"Anesth. Prog."},{"key":"B13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12871-019-0847-y","article-title":"Sub-hypnotic dose of propofol as antiemetic prophylaxis attenuates intrathecal morphine-induced postoperative nausea and vomiting, and pruritus in parturients undergoing cesarean section: a randomized controlled trial","volume":"19","author":"Kampo","year":"2019","journal-title":"BMC Anesthesiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/ejp.1652","article-title":"Six-year trends in postoperative prescribing and use of multimodal analgesics following total hip and knee arthroplasty: a single-site observational study of pain management","volume":"25","author":"Khaw","year":"2021","journal-title":"Eur. J. Pain"},{"key":"B15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00101-021-01045-z","article-title":"Update on PONV-what is new in prophylaxis and treatment of postoperative nausea and vomiting? Summary of recent consensus recommendations and cochrane reviews on prophylaxis and treatment of postoperative nausea and vomiting","volume":"71","author":"Kienbaum","year":"2022","journal-title":"Anaesthesist"},{"key":"B16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12871-017-0357-8","article-title":"Combination of gabapentin and ramosetron for the prevention of postoperative nausea and vomiting after gynecologic laparoscopic surgery: a prospective randomized comparative study","volume":"17","author":"Kim","year":"2017","journal-title":"BMC Anesthesiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.17085\/apm.23142","article-title":"Association between preoperative lumbar skeletal muscle index and postoperative nausea and vomiting in patients undergoing pylorus-preserving pancreatoduodenectomy: a retrospective study","volume":"19","author":"Kim","year":"2024","journal-title":"Anesth. Pain Med. Seoul."},{"key":"B18","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/ALN.0000000000003485","article-title":"Anesthetic and analgesic drug products advisory committee activity and decisions in the opioid-crisis era","volume":"133","author":"Litman","year":"2020","journal-title":"Anesthesiology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"16346","DOI":"10.1073\/pnas.1918264117","article-title":"Mechanism of \u03b2-arrestin recruitment by the \u03bc-opioid G protein-coupled receptor","volume":"117","author":"Mafi","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e50633","DOI":"10.7759\/cureus.50633","article-title":"Challenges and opportunities in developing tailored pain management strategies for liver patients","volume":"15","author":"Majid","year":"2023","journal-title":"Cureus"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1007\/s40265-020-01414-9","article-title":"Oliceridine: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"B22","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1097\/ALN.0000000000004758","article-title":"Neurocognitive effect of biased \u00b5-opioid receptor agonist oliceridine, a utility function analysis and comparison with morphine","volume":"139","author":"Moss","year":"2023","journal-title":"Anesthesiology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1369442","DOI":"10.3389\/fphar.2024.1369442","article-title":"Research trends on chemotherapy-induced nausea and vomiting: a bibliometric analysis","volume":"15","author":"Ni","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1080\/17512433.2023.2213889","article-title":"Efficacy and safety of oliceridine treatment in patients with postoperative pain: a systematic review and meta-analysis of randomized controlled trials","volume":"16","author":"Nie","year":"2023","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"106961","DOI":"10.1016\/j.phrs.2023.106961","article-title":"IUPHAR themed review: opioid efficacy, bias, and selectivity","volume":"197","author":"Ramos-Gonzalez","year":"2023","journal-title":"Pharmacol. Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/ACO.0000000000001220","article-title":"Postoperative nausea and vomiting: risk factors, prediction tools, and algorithms","volume":"36","author":"Schlesinger","year":"2023","journal-title":"Curr. Opin. Anaesthesiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e5969","DOI":"10.1097\/GOX.0000000000005969","article-title":"Emesis as a risk factor for postoperative hematoma in abdominoplasty: a retrospective study in 189 cases","volume":"12","author":"Scharfetter","year":"2024","journal-title":"Plast. Reconstr. Surg. Glob. Open"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e19076","DOI":"10.7759\/cureus.19076","article-title":"A dive into oliceridine and its novel mechanism of action","volume":"13","author":"Shah","year":"2021","journal-title":"Cureus"},{"key":"B29","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/ALN.0000000000004473","article-title":"Respiratory effects of biased ligand oliceridine in older volunteers: a pharmacokinetic-pharmacodynamic comparison with morphine","volume":"138","author":"Simons","year":"2023","journal-title":"Anesthesiology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.2147\/JPR.S137952","article-title":"A randomized, phase IIb study investigating oliceridine (TRV130), a novel \u03bc-receptor G-protein pathway selective (\u03bc-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty","volume":"10","author":"Singla","year":"2017","journal-title":"J. Pain Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/papr.12801","article-title":"APOLLO-2: a randomized, placebo- and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the \u03bc-opioid receptor, for management of moderate to severe acute pain following abdominoplasty","volume":"19","author":"Singla","year":"2019","journal-title":"Pain Pract."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1111\/bph.15409","article-title":"TRV130 partial agonism and capacity to induce anti-nociceptive tolerance revealed through reducing available \u03bc-opioid receptor number","volume":"178","author":"Singleton","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/j.pain.2014.06.011","article-title":"Biased agonism of the \u03bc-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers","volume":"155","author":"Soergel","year":"2014","journal-title":"Pain"},{"key":"B34","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/j.pain.0000000000000363","article-title":"A randomized, phase 2 study investigating TRV130, a biased ligand of the \u03bc-opioid receptor, for the intravenous treatment of acute pain","volume":"157","author":"Viscusi","year":"2016","journal-title":"Pain"},{"key":"B35","doi-asserted-by":"publisher","first-page":"927","DOI":"10.2147\/JPR.S171013","article-title":"APOLLO-1: a randomized placebo- and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the \u03bc-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy","volume":"12","author":"Viscusi","year":"2019","journal-title":"J. Pain Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1111\/bph.14702","article-title":"The G-protein-biased agents PZM21 and TRV130 are partial agonists of \u03bc-opioid receptor-mediated signalling to ion channels","volume":"176","author":"Yekkirala","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e0231958","DOI":"10.1371\/journal.pone.0231958","article-title":"Effects of intravenous dextrose on preventing postoperative nausea and vomiting: a systematic review and meta-analysis with trial sequential analysis","volume":"15","author":"Yokoyama","year":"2020","journal-title":"PLoS One"},{"key":"B38","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12871-024-02469-x","article-title":"Efficacy of transversus abdominis plane block on postoperative nausea and vomiting: a meta-analysis of randomized controlled trials","volume":"24","author":"Zeng","year":"2024","journal-title":"BMC Anesthesiol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1779641\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:53:20Z","timestamp":1776837200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1779641\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":38,"alternative-id":["10.3389\/fphar.2026.1779641"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1779641","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"article-number":"1779641"}}